Insights into the classification of myasthenia gravis

PLoS One. 2014 Sep 5;9(9):e106757. doi: 10.1371/journal.pone.0106757. eCollection 2014.

Abstract

Background and purpose: Myasthenia gravis (MG) is often categorized into thymoma-associated MG, early-onset MG with onset age <50 years, and late-onset MG with onset age ≥50 years. However, the boundary age of 50 years old between early- and late-onset MG remains controversial, and each category contains further subtypes. We attempted to classify MG from a statistical perspective.

Methods: We analyzed 640 consecutive MG patients using two-step cluster analysis with clinical variables and discrimination analysis, using onset age as a variable.

Results: Two-step cluster analyses categorized MG patients into the following five subtypes: ocular MG; MG with thymic hyperplasia (THMG); generalized anti-acetylcholine receptor antibody (AChR-Ab)-negative MG; thymoma-associated MG; and generalized AChR-Ab-positive (SP) MG without thymic abnormalities. Among these 5 subtypes, THMG showed a distribution of onset age skewed toward a younger age (p<0.01), whereas ocular MG and SPMG without thymic abnormalities showed onset age skewed toward an older age (p<0.001 and p<0.0001, respectively). The other 2 subtypes showed normal distributions. THMG appeared as the main component of early-onset MG, and ocular MG and SPMG without thymic abnormalities as the main components of late-onset MG. Discrimination analyses between THMG and ocular MG and/or SPMG without thymic abnormalities demonstrated a boundary age of 45 years old.

Conclusions: From a statistical perspective, the boundary age between early- and late-onset MG is about 45 years old.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Cluster Analysis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical*
  • Myasthenia Gravis / immunology*
  • Myasthenia Gravis / pathology*
  • Thymoma / complications
  • Thymoma / immunology
  • Thymoma / pathology
  • Thymus Neoplasms / complications
  • Thymus Neoplasms / immunology
  • Thymus Neoplasms / pathology
  • Young Adult

Grants and funding

This work was supported by a fund of the Japan MG registry study group and by a Neuroimmunological Disease Research Committee Grant from the Japanese Ministry of Health, Labour, and Welfare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.